Redifferentiation  	Redifferentiation  	 NNP	B-NP
of  	of  	 IN	O
iodine-refractory  	iodine-refractory  	 FW	O
BRAF  	BRAF  	 FW	O
V600E-mutant  	V600E-mutant  	 FW	O
metastatic  	metastatic  	 FW	O
papillary  	papillary  	 FW	O
thyroid  	thyroid  	 FW	O
cancer  	cancer  	 NN	O
with  	with  	 IN	O
dabrafenib  	dabrafenib  	 VBG	O
To  	To  	 TO	O
determine  	determine  	 VB	O
whether  	whether  	 IN	O
the  	the  	 DT	O
selective  	selective  	 JJ	B-NP
BRAF  	BRAF  	 NNP	I-NP
inhibitor 	inhibitor 	 NN	I-NP
,  	,  	 ,	O
dabrafenib 	dabrafenib 	 NN	B-NP
,  	,  	 ,	O
can  	can  	 MD	O
stimulate  	stimulate  	 VB	O
radioiodine  	radioiodine  	 JJ	B-NP
uptake  	uptake  	 NN	I-NP
in  	in  	 IN	O
BRAF  	BRAF  	 NNP	O
V600E-mutated  	V600E-mutated  	 NNP	O
unresectable  	unresectable  	 NN	O
or  	or  	 CC	O
metastatic  	metastatic  	 JJ	B-NP
iodine-refractory  	iodine-refractory  	 JJ	I-NP
papillary  	papillary  	 JJ	I-NP
thyroid  	thyroid  	 JJ	I-NP
cancer  	cancer  	 NN	I-NP
( 	( 	 -LRB-	O
PTC 	PTC 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
Ten  	Ten  	 CD	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
BRAF  	BRAF  	 NNP	O
V600E-mutant  	V600E-mutant  	 NNP	O
iodine-refractory  	iodine-refractory  	 NNP	O
PTC  	PTC  	 NNP	O
were  	were  	 VBD	O
enrolled 	enrolled 	 VBN	O
.  	.  	 .	O
Absence  	Absence  	 NN	B-NP
of  	of  	 IN	I-NP
radioiodine  	radioiodine  	 JJ	I-NP
uptake  	uptake  	 NN	I-NP
on  	on  	 IN	O
iodine-131  	iodine-131  	 CD	B-NP
whole  	whole  	 JJ	O
body  	body  	 NN	O
scan  	scan  	 VBZ	O
obtained  	obtained  	 VBN	O
within  	within  	 IN	O
14  	14  	 CD	O
months  	months  	 NNS	O
of  	of  	 IN	O
study  	study  	 NN	B-NP
entry  	entry  	 NN	I-NP
was  	was  	 VBD	O
required 	required 	 VBN	O
.  	.  	 .	O
Each  	Each  	 DT	O
patient  	patient  	 NN	O
received  	received  	 VBD	B-NP
dabrafenib  	dabrafenib  	 NNS	I-NP
( 	( 	 -LRB-	O
150  	150  	 CD	O
mg  	mg  	 NNS	B-NP
twice  	twice  	 RB	O
daily 	daily 	 JJ	O
)  	)  	 -RRB-	O
for  	for  	 IN	O
25  	25  	 CD	O
days  	days  	 NNS	O
before  	before  	 IN	O
thyrotropin  	thyrotropin  	 JJ	B-NP
α-stimulated  	α-stimulated  	 JJ	I-NP
iodine-131  	iodine-131  	 CD	I-NP
whole  	whole  	 JJ	O
body  	body  	 NN	O
scan  	scan  	 NNS	O
( 	( 	 -LRB-	O
4  	4  	 CD	O
mCi 	mCi 	 JJ	O
/ 	/ 	 CD	O
148  	148  	 CD	O
MBq 	MBq 	 NN	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
Patients  	Patients  	 NNS	O
whose  	whose  	 WP$	O
scan  	scan  	 NNS	O
showed  	showed  	 VBD	O
new  	new  	 JJ	O
sites  	sites  	 NNS	O
of  	of  	 IN	O
radioiodine  	radioiodine  	 JJ	B-NP
uptake  	uptake  	 NN	I-NP
remained  	remained  	 VBD	O
on  	on  	 IN	O
dabrafenib  	dabrafenib  	 NN	B-NP
for  	for  	 IN	O
17  	17  	 CD	O
more  	more  	 JJR	O
days 	days 	 NNS	O
,  	,  	 ,	O
and  	and  	 CC	O
then  	then  	 RB	O
were  	were  	 VBD	O
treated  	treated  	 VBN	O
with  	with  	 IN	O
150  	150  	 CD	O
mCi  	mCi  	 NNS	O
( 	( 	 -LRB-	O
5.5  	5.5  	 CD	O
GBq 	GBq 	 NN	B-NP
)  	)  	 -RRB-	O
iodine-131 	iodine-131 	 NNP	B-NP
.  	.  	 .	O
The  	The  	 DT	O
primary  	primary  	 JJ	B-NP
endpoint  	endpoint  	 NN	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
study  	study  	 NN	O
was  	was  	 VBD	O
the  	the  	 DT	O
percentage  	percentage  	 NN	O
of  	of  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
new  	new  	 JJ	O
radioiodine  	radioiodine  	 JJ	B-NP
uptake  	uptake  	 NN	I-NP
after  	after  	 IN	O
treatment  	treatment  	 NN	O
with  	with  	 IN	O
dabrafenib 	dabrafenib 	 NN	B-NP
.  	.  	 .	O
Six  	Six  	 CD	O
of  	of  	 IN	O
10  	10  	 CD	O
patients  	patients  	 NNS	O
( 	( 	 -LRB-	O
60 	60 	 CD	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
demonstrated  	demonstrated  	 VBD	O
new  	new  	 JJ	O
radioiodine  	radioiodine  	 JJ	B-NP
uptake  	uptake  	 NN	I-NP
on  	on  	 IN	O
whole  	whole  	 JJ	O
body  	body  	 NN	O
scan  	scan  	 NN	O
after  	after  	 IN	O
treatment  	treatment  	 NN	O
with  	with  	 IN	O
dabrafenib 	dabrafenib 	 NN	B-NP
.  	.  	 .	O
All  	All  	 DT	O
6  	6  	 CD	O
were  	were  	 VBD	O
treated  	treated  	 VBN	O
with  	with  	 IN	O
5.5  	5.5  	 CD	O
GBq  	GBq  	 JJ	B-NP
iodine-131 	iodine-131 	 NN	I-NP
.  	.  	 .	O
Two  	Two  	 CD	O
patients  	patients  	 NNS	O
had  	had  	 VBD	O
partial  	partial  	 JJ	O
responses  	responses  	 NNS	O
and  	and  	 CC	O
4  	4  	 CD	O
patients  	patients  	 NNS	O
had  	had  	 VBD	O
stable  	stable  	 JJ	O
disease  	disease  	 NN	O
on  	on  	 IN	O
standard  	standard  	 JJ	O
radiographic  	radiographic  	 JJ	B-NP
restaging  	restaging  	 NN	I-NP
at  	at  	 IN	O
3  	3  	 CD	O
months 	months 	 NNS	O
.  	.  	 .	O
Thyroglobulin  	Thyroglobulin  	 NNP	B-NP
decreased  	decreased  	 VBD	O
in  	in  	 IN	O
4  	4  	 CD	O
of  	of  	 IN	O
6  	6  	 CD	O
treated  	treated  	 CD	O
patients 	patients 	 NNS	O
.  	.  	 .	O
One  	One  	 CD	O
patient  	patient  	 NN	O
developed  	developed  	 VBD	O
squamous  	squamous  	 JJ	B-NP
cell  	cell  	 NN	I-NP
carcinoma  	carcinoma  	 NN	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
skin 	skin 	 NN	O
.  	.  	 .	O
There  	There  	 EX	O
were  	were  	 VBD	O
no  	no  	 DT	O
other  	other  	 JJ	O
significant  	significant  	 JJ	O
adverse  	adverse  	 JJ	O
events  	events  	 NNS	O
attributed  	attributed  	 VBD	O
to  	to  	 TO	O
dabrafenib 	dabrafenib 	 VB	O
.  	.  	 .	O
Dabrafenib  	Dabrafenib  	 NNP	B-NP
can  	can  	 MD	O
stimulate  	stimulate  	 VB	O
radioiodine  	radioiodine  	 JJ	B-NP
uptake  	uptake  	 NN	I-NP
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
metastatic  	metastatic  	 JJ	O
BRAF  	BRAF  	 NNP	O
V600E-mutant  	V600E-mutant  	 NNP	O
iodine-refractory  	iodine-refractory  	 NNP	O
PTC 	PTC 	 NNP	O
,  	,  	 ,	O
representing  	representing  	 VBG	O
a  	a  	 DT	O
potential  	potential  	 JJ	B-NP
new  	new  	 JJ	I-NP
therapeutic  	therapeutic  	 JJ	I-NP
approach  	approach  	 NN	I-NP
for  	for  	 IN	O
these  	these  	 DT	O
patients 	patients 	 NNS	O
.  	.  	 .	O
